Quantum Biopharma Ltd.
corporate_fare Company Profile
Quantum Biopharma Ltd. (NASDAQ:QNTM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for QNTM at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Quantum BioPharma's Novel MS Drug, Lucid-MS, Enters Phase 2 Clinical Trial
- Quantum Biopharma Secures Cash Runway to 2028, Maintains 'No Going Concern' Status
- Quantum Biopharma Secures Cash Runway to 2028, Eliminating Going Concern Risk
- Annual Report Reveals Deeply Dilutive Financing, Mounting Losses, and Going Concern Risk Amidst Risky Crypto Strategy
- Renowned MS Neurologist to Lead Quantum Biopharma's Planned Phase 2 Lucid-MS Trial
Insider Transactions
QNTM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.